title: [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
abstract: In nine patients with advanced acute or chronic leukemia, we performed allogeneic hematopoietic stem cell transplantation (HSCT) following a modified myeloablative conditioning regimen intended to optimize the intensity of conditioning. This regimen consisted of intravenous busulfan 8mg/kg, cyclophosphamide 120mg/kg and total lymphoid irradiation 7.5 Gy. The median age of the patients was 30 years (range 18-59). Stem cell sources were related bone marrow in two, related peripheral blood in one, and unrelated bone marrow in six patients. Prophylaxis against acute graft-versus-host disease (GVHD) was cyclosporine and short-term methotrexate. Acute GVHD appeared in six patients (67%), grade II in all. Extensive chronic GVHD occurred in three of seven evaluable patients. The median follow-up period after HSCT was 813 days (248- 1,702). Of nine patients, five relapsed or progressed after HSCT. However, no patient relapsed or progressed within 100 days after HSCT. During the full follow-up period, transplant-related mortality (TRM) was not observed. The two-year overall survival and event-free survival were 88.9% and 50.0%, respectively. Our results suggested that we might reduce the incidence of TRM and simultaneously control disease by using an optimized conditioning regimen for HSCT.
authors.affiliation: Dept. of Hematology, Graduate School of Medicine, Osaka City University, Japan.
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Nakamae
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Terada
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nakane
authors.forename: Hideo
authors.initials: H
authors.lastname: Koh
authors.forename: Mika
authors.initials: M
authors.lastname: Nakamae
authors.forename: Ran
authors.initials: R
authors.lastname: Aimoto
authors.forename: Asao
authors.initials: A
authors.lastname: Hirose
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Mitsutaka
authors.initials: M
authors.lastname: Nishimoto
authors.forename: Eri
authors.initials: E
authors.lastname: Inoue
authors.forename: Takuro
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Atsushi
authors.initials: A
authors.lastname: Inoue
authors.forename: Ki-Ryang
authors.initials: KR
authors.lastname: Koh
authors.forename: Takahisa
authors.initials: T
authors.lastname: Yamane
authors.forename: Masayuki
authors.initials: M
authors.lastname: Hino
mesh_terms: D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000008:administration & dosage / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology*; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D007262:Infusions, Intravenous; D007938:Leukemia / Q000473:pathology / Q000601:surgery*; D015182:Lymphatic Irradiation; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D002066:Busulfan